Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

Operational review meeting minutes released by the Department of Health and Social Care (DHSC) reveal that the industry and ...

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...

A study has shown that the efficacy of Eli Lilly's psoriasis therapy Taltz is improved when it is given in combination with ...

AstraZeneca has already filed for approval of its therapy for ultra-rare disease hypophosphatasia (HPP), after missing the ...

Expectations for Wnt pathway-targeting trispecific antibody remigromig (MK-3000, formerly known as EYE103) were riding high ...

For years, medtech companies have treated the digital experience around their devices as an afterthought. A layer of software ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...

Shares in Vaxcyte have rocketed on the revelation of phase 3 trial data for its pneumococcal vaccine (PCV) candidate VAX-31, ...